YU295A - PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C - Google Patents

PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C

Info

Publication number
YU295A
YU295A YU295A YU295A YU295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A
Authority
YU
Yugoslavia
Prior art keywords
apc
procedures
protein degradation
preventing protein
autodegradation
Prior art date
Application number
YU295A
Other languages
Serbo-Croatian (sh)
Inventor
F.W. Prouty
J. Secnik
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU295A publication Critical patent/YU295A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to methods to prevent or minimize autodegradation of activated protein C. The invention is best exemplified by performing the processing, purification and/or storage of the activated protein C at low pH, for example at about pH 6.3 to about pH 6.5. Autodegradation of aPC may also be minimized by incubating the aPC in 3 M urea (complete recovery of aPC activity is obtained after the removal of the denaturant) or by incubating the aPC in the presence of extreme salt concentrations. The present invention also comprises aPC formulations which maintain the aPC at low pH, in denaturant, or at extreme salt concentrations.
YU295A 1994-01-05 1995-01-04 PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C YU295A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05

Publications (1)

Publication Number Publication Date
YU295A true YU295A (en) 1997-09-30

Family

ID=22650141

Family Applications (1)

Application Number Title Priority Date Filing Date
YU295A YU295A (en) 1994-01-05 1995-01-04 PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C

Country Status (29)

Country Link
EP (2) EP1087011A3 (en)
JP (1) JP3778588B2 (en)
KR (1) KR950032287A (en)
CN (1) CN1109891A (en)
AT (1) ATE201045T1 (en)
AU (1) AU1003195A (en)
BR (1) BR9500017A (en)
CA (1) CA2139468C (en)
CO (1) CO4600680A1 (en)
CZ (1) CZ1395A3 (en)
DE (2) DE10299053I2 (en)
DK (1) DK0662513T3 (en)
ES (1) ES2156190T3 (en)
FI (1) FI115635B (en)
GR (1) GR3036277T3 (en)
HU (1) HUT70465A (en)
IL (1) IL112236A (en)
LU (2) LU90992I2 (en)
NL (1) NL300108I2 (en)
NO (2) NO320157B1 (en)
NZ (1) NZ270271A (en)
PE (1) PE43995A1 (en)
PL (1) PL180703B1 (en)
PT (1) PT662513E (en)
RU (1) RU2167936C2 (en)
SI (1) SI0662513T1 (en)
UA (1) UA39178C2 (en)
YU (1) YU295A (en)
ZA (1) ZA9514B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132325A (en) 1997-04-28 2005-07-25 Lilly Co Eli Activated protein c formulations
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402262B (en) * 1991-06-20 1997-03-25 Immuno Ag MEDICINAL ACTIVATED PROTEIN C

Also Published As

Publication number Publication date
DE69520844T2 (en) 2001-11-08
NO2006006I1 (en) 2006-05-15
NO950018D0 (en) 1995-01-03
EP1087011A2 (en) 2001-03-28
LU90992I2 (en) 2003-02-18
NO320157B1 (en) 2005-11-07
CA2139468C (en) 2007-08-21
KR950032287A (en) 1995-12-20
SI0662513T1 (en) 2001-10-31
PL306671A1 (en) 1995-07-10
CO4600680A1 (en) 1998-05-08
CN1109891A (en) 1995-10-11
FI950044A0 (en) 1995-01-04
HU9500021D0 (en) 1995-03-28
EP0662513A1 (en) 1995-07-12
JP3778588B2 (en) 2006-05-24
DE10299053I1 (en) 2003-05-22
ATE201045T1 (en) 2001-05-15
UA39178C2 (en) 2001-06-15
HUT70465A (en) 1995-10-30
DE69520844D1 (en) 2001-06-13
LU90993I2 (en) 2003-02-18
RU95100178A (en) 1997-03-27
IL112236A0 (en) 1995-03-30
CZ1395A3 (en) 1995-07-12
GR3036277T3 (en) 2001-10-31
NO950018L (en) 1995-07-06
BR9500017A (en) 1995-10-03
ES2156190T3 (en) 2001-06-16
ZA9514B (en) 1996-07-03
RU2167936C2 (en) 2001-05-27
PE43995A1 (en) 1995-12-15
DK0662513T3 (en) 2001-05-28
EP1087011A3 (en) 2002-02-06
FI115635B (en) 2005-06-15
DE10299053I2 (en) 2004-04-01
IL112236A (en) 1999-12-31
CA2139468A1 (en) 1995-07-06
AU1003195A (en) 1995-07-13
PL180703B1 (en) 2001-03-30
NL300108I2 (en) 2003-06-02
JPH07206704A (en) 1995-08-08
FI950044A (en) 1995-07-06
NZ270271A (en) 1996-07-26
NL300108I1 (en) 2003-02-03
PT662513E (en) 2001-08-30
EP0662513B1 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
DK83093D0 (en) COURSE OF ACTION
EA199900980A1 (en) IMPROVED WAYS TO PREPARE ACTIVATED PROTEIN C
DE69432035D1 (en) Saccharin derivatives as proteolytic enzyme inhibitors
DE69232929D1 (en) Saccharin derivatives as proteolytic enzyme inhibitors
NO2006006I1 (en) Activated Protein C
DE69011622D1 (en) Use of protected amino acids in animal feed for sheep.
DE69227805T2 (en) Use of tri-n-butyl phosphate at low pH in solutions of biologically active proteins for an improved virucidal effect
GR1001480B (en) Enzyme preparations containing papain or chymothrypsin and methods for permanent hair removing.
ATE220678T1 (en) METHOD FOR OBTAINING HEMIN FROM SLAUGHTER BLOOD
ATE139118T1 (en) RIBOZYMINE INHIBITORS
TH19245A (en) How to prevent the breakdown of protein C